论文信息 - Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. - 字舞流文

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.

M. Kersten | J. Radford | R. Malladi | P. Dreger | K. Davison | K. Dorritie | N. Joshi | I. Avivi | J. Chavez | S. Jaglowski | G. Enblad | F. Morschhauser | C. Thieblemont | K. Osman | S. Dahiya | M. Elsawy | D. Tzachanis | L. Wannesson | R. Karmali | N. Kekre | K. Cwynarski | J. Rudzki | M. Ulrickson | D. Cunningham | Wei-Jhih Wang | C. Solem | J. Snider | P. Cheng | J. Larouche | A. Martín García-Sancho | C. To